Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
ACADIA Pharmaceuticals Inc is a biotechnology business based in the US. ACADIA Pharmaceuticals shares (ACAD) are listed on the NASDAQ and all prices are listed in US Dollars. ACADIA Pharmaceuticals employs 580 staff and has a trailing 12-month revenue of around USD$419.1 million.
Since the stock market crash in March caused by coronavirus, ACADIA Pharmaceuticals's share price has had significant negative movement.
Its last market close was USD$41.49, which is 8.07% down on its pre-crash value of USD$45.13 and 38.21% up on the lowest point reached during the March crash when the shares fell as low as USD$30.02.
If you had bought USD$1,000 worth of ACADIA Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$855.75 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,014.43.
|Latest market close||USD$41.49|
|52-week range||USD$30.02 - USD$58.72|
|50-day moving average||USD$47.4933|
|200-day moving average||USD$45.7681|
|Wall St. target price||USD$59.61|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.966|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-24)||-24.18%|
|1 month (2020-10-30)||-10.68%|
|3 months (2020-09-01)||8.95%|
|6 months (2020-06-01)||-15.14%|
|1 year (2019-11-29)||-8.39%|
|2 years (2018-11-30)||117.68%|
|3 years (2017-12-01)||37.57%|
|5 years (2015-12-01)||10.61%|
|Revenue TTM||USD$419.1 million|
|Gross profit TTM||USD$79.1 million|
|Return on assets TTM||-17.86%|
|Return on equity TTM||-39.86%|
|Market capitalisation||USD$8.9 billion|
TTM: trailing 12 months
There are currently 8.8 million ACADIA Pharmaceuticals shares held short by investors – that's known as ACADIA Pharmaceuticals's "short interest". This figure is 0.6% down from 8.9 million last month.
There are a few different ways that this level of interest in shorting ACADIA Pharmaceuticals shares can be evaluated.
ACADIA Pharmaceuticals's "short interest ratio" (SIR) is the quantity of ACADIA Pharmaceuticals shares currently shorted divided by the average quantity of ACADIA Pharmaceuticals shares traded daily (recently around 1.2 million). ACADIA Pharmaceuticals's SIR currently stands at 7.46. In other words for every 100,000 ACADIA Pharmaceuticals shares traded daily on the market, roughly 7460 shares are currently held short.
However ACADIA Pharmaceuticals's short interest can also be evaluated against the total number of ACADIA Pharmaceuticals shares, or, against the total number of tradable ACADIA Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ACADIA Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 ACADIA Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0877% of the tradable shares (for every 100,000 tradable ACADIA Pharmaceuticals shares, roughly 88 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ACADIA Pharmaceuticals.
Find out more about how you can short ACADIA Pharmaceuticals stock.
We're not expecting ACADIA Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, ACADIA Pharmaceuticals's shares have ranged in value from as little as $30.02 up to $58.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ACADIA Pharmaceuticals's is 1.4267. This would suggest that ACADIA Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.